Key Insights

Given the large stake in the stock by institutions, Inhibrx Biosciences' stock price might be vulnerable to their trading decisions A total of 7 investors have a majority stake in the company with 50% ownership Insiders have bought recently

A look at the shareholders of Inhibrx Biosciences, Inc. (NASDAQ:INBX) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 43% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

And following last week's 15% decline in share price, institutional suffered the most losses.

Let's take a closer look to see what the different types of shareholders can tell us about Inhibrx Biosciences.

See our latest analysis for Inhibrx Biosciences NasdaqGS:INBX Ownership Breakdown November 17th 2024

What Does The Institutional Ownership Tell Us About Inhibrx Biosciences?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Inhibrx Biosciences. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Inhibrx Biosciences' historic earnings and revenue below, but keep in mind there's always more to the story.NasdaqGS:INBX Earnings and Revenue Growth November 17th 2024

Our data indicates that hedge funds own 12% of Inhibrx Biosciences. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. The company's largest shareholder is Viking Global Investors LP, with ownership of 12%. For context, the second largest shareholder holds about 8.0% of the shares outstanding, followed by an ownership of 7.6% by the third-largest shareholder. John Kayyem, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. In addition, we found that Mark Lappe, the CEO has 6.4% of the shares allocated to their name.

Story Continues

On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.

Insider Ownership Of Inhibrx Biosciences

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our information suggests that insiders maintain a significant holding in Inhibrx Biosciences, Inc.. Insiders have a US$39m stake in this US$200m business. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can  click here to see if those insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 10% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With a stake of 7.4%, private equity firms could influence the Inhibrx Biosciences board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Public Company Ownership

It appears to us that public companies own 8.0% of Inhibrx Biosciences. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Inhibrx Biosciences better, we need to consider many other factors. To that end, you should be aware of the  3 warning signs  we've spotted with Inhibrx Biosciences .

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this freelist of interesting companies.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments